SundarJagannathMD

Hematologic Oncology

Mt. Sinai Myeloma Program

Overview of Dr. Jagannath

Dr. Sundar Jagannath is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital and Mount Sinai West. He received his medical degree from Baroda Medical College and has been in practice 41 years. Dr. Jagannath accepts several types of health insurance, listed below. He is one of 191 doctors at The Mount Sinai Hospital and one of 75 doctors at Mount Sinai West who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
1 Gustave L. Levy Place, Box 1185
Mount Sinai Medical Center
New York, NY 10029
Book by Phone+1(325) 399-7577

Fax+1 212-241-3908
Is this information wrong?

Education & Training

University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1980 - 1982
Wayne State University School of MedicineResidency, Internal Medicine, 1979 - 1980
BronxCare Health SystemResidency, Internal Medicine, 1977 - 1979
Baroda Medical CollegeClass of 1976

Certifications & Licensure

NJ State Medical License 2017 - 2025
FL State Medical License 2017 - 2025
NY State Medical License 1998 - 2025
MI State Medical License 1979 - 2020
TX State Medical License 1980 - 2011
AR State Medical License 1989 - 2000
MD State Medical License 1979 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2002-2014
New York Magazine: Top Doctors Castle Connolly, 2004, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma Start of enrollment: 2005 Jun 01
Completed
Phase 1
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma Start of enrollment: 2008 Dec 01
Withdrawn
Phase 1
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma Start of enrollment: 2007 May 01
Completed
Phase 1
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma Start of enrollment: 2008 Mar 01
Completed
Phase 2
Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma Start of enrollment: 2008 Sep 01
Terminated
Phase 2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide Start of enrollment: 2011 Nov 01
Completed
Phase 1, Phase 2
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2012 Jan 01
Completed
Phase 1
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) Start of enrollment: 2012 Jul 01
Completed
Phase 2
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Start of enrollment: 2013 Sep 01
Completed
Phase 2
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM Start of enrollment: 2019 Oct 24
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
Keren Osman, Adolfo Aleman, Selma Bekri, Simone Kats, Amishi Dhadwal, Donna Catamero, Seunghee Kim-Schulze, Sacha Gnjatic, Samir Parekh, David G Coffey, Ajai Chari, Su...> ;Journal for Immunotherapy of Cancer. 2024 Apr 12
Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable.
Shune, L., Ailawadhi, S., Wong, S., Lin, Y., Patel, K., Jagannath, S.> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 1
Regression of smoldering myeloma with treatment of Gaucher disease.
Kevin Barley, Anshuman Parekh, Deepa Vatti, Daniel Verina, Violetta V Leshchenko, Sundar Jagannath, Manisha Balwani, Syed Salam, Damodara Rao Mendu, Ravi Prakash Shukl...> ;Blood Advances. 2024 Apr 9
3 citations
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Urvi A Shah, Erin Moshier, Andriy Derkach, Yuanhui Huang, Sham Mailankody, Carlyn R Tan, Kylee Maclachlan, Malin Hultcrantz, Neha Korde, Hani Hassoun, Santiago Thibaud...> ;Blood Advances. 2024 Jan 9
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.
Stevens, M., Kimmerling, R., Olcum, S., Vacha, M., LaBella, R., Minnah, A., Katsis, K., Fujii, J., Shaheen, Z., Sundaresan, S., Criscitiello, J., Niesvizky, R., Raje, ...> ;JCO Precision Oncology. 2024 Jan 1
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.
Adolfo Aleman, Morgan van Kesteren, Ariel Kogan Zajdman, Komal Srivastava, Christian Cognigni, Jacob Mischka, Lucia Y Chen, Bhaskar Upadhyaya, Kseniya Serebryakova, Je...> ;Ebiomedicine. 2023 Dec 1
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
Leslie Ballas, Sikander Ailawadhi, Mohit Narang, Cristina J Gasparetto, Hans C Lee, James W Hardin, Brian G M Durie, Kathleen Toomey, James Omel, Lynne I Wagner, Rafat...> ;Practical Radiation Oncology. 2023 Nov 19
4 citations
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
Guido Lancman, Kian Parsa, Krzysztof Kotlarz, Lisa Avery, Alaina Lurie, Alex Lieberman-Cribbin, Hearn Jay Cho, Samir S Parekh, Shambavi Richard, Joshua Richter, Adrian...> ;Blood Cancer Discovery. 2023 Nov 1
Case 29-2023: A 34-Year-Old Woman with Abdominal Distention and Acute Kidney Injury.
Sundar Jagannath, Mark A Anderson, Andrew J Yee, Robert P Hasserjian> ;The New England Journal of Medicine. 2023 Sep 21
1 citations
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study.
Sundar Jagannath, Sosana Delimpasi, Sebastian Grosicki, Dane R Van Domelen, Ohad S Bentur, Ivan Špička, Meletios A Dimopoulos> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Dec 1
2 citations
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Myo Htut, Binod Dhakal, Adam D Cohen, Thomas Martin, Jesus G Berdeja, Saad Z Usmani, Mounzer Agha, Carolyn C Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Dec 1
8 citations
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Yi Lin, Noopur S Raje, Jesús G Berdeja, David S Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Monica Massaro, Fabio Pe...> ;Nature Medicine. 2023 Sep 1
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
Jesus G Berdeja, Adam D Cohen, Thomas Martin, Deepu Madduri, Lida Pacaud, Sundar Jagannath> ;Future Oncology. 2023 Jun 1
Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.
Stephen Palmer, Yi Lin, Thomas G Martin, Sundar Jagannath, Andrzej Jakubowiak, Saad Z Usmani, Nasuh Buyukkaramikli, Hilary Phelps, Rafal Slowik, Feng Pan, Satish Vallu...> ;Oncology and Therapy. 2023 Sep 1
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David Melnekoff, Christos Adamopoulos, Mark M Stevens, Katerina Kappes, Violetta Leshchenko, Daniel Verina...> ;Journal of Hematology & Oncology. 2023 May 8
What Affects Treatment Underuse in Multiple Myeloma in the United States: A Qualitative Study.
Rose Cytryn, Nina Bickell, Radhi Yagnik, Sundar Jagannath, Jenny J Lin> ;Cancers. 2023 Apr 19
4 citations
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
Sundar Jagannath, Nedra Joseph, Concetta Crivera, Akshay Kharat, Carolyn C Jackson, Satish Valluri, Patricia Cost, Hilary Phelps, Rafal Slowik, Timothy Klein, Lee Smol...> ;Oncology and Therapy. 2023 Jun 1
3 citations
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop.
Evangelos Terpos, Paola Neri, Niels W C J van de Donk, Mattia D'Agostino, Samir Parekh, Sundar Jagannath, Heinz Ludwig, David E Avigan, Noopur S Raje, Dhodapkar, M.> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jun 1
4 citations
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findin...
Hans C Lee, Karthik Ramasamy, Katja Weisel, Rafat Abonour, James W Hardin, Robert M Rifkin, Sikander Ailawadhi, Howard R Terebelo, Brian G M Durie, Derek Tang, Prashan...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Feb 1
7 citations
Adjusted comparison of outcomes between patients from CARTITUDE-1multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and ant...
Maria-Victoria Mateos, Katja Weisel, Thomas Martin, Jesús G Berdeja, Andrzej Jakubowiak, A Keith Stewart, Sundar Jagannath, Yi Lin, Joris Diels, Francesca Ghilotti, Pu...> ;Haematologica. 2023 Aug 1
2 citations
Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States.
Sundar Jagannath, Nedra Joseph, Jinghua He, Concetta Crivera, Alex Z Fu, Ashraf Garrett, Nina Shah> ;Oncology and Therapy. 2022 Dec 1
22 citations
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, Tasmin Farzana, Adolfo Aleman, David T Melnekoff, Yogita Ghodke-Puranik, Gunjan L Shah, Alexander Lesokhin, Serg...> ;Blood. 2023 Feb 16
24 citations
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/...
Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G Richardson, Thierry Facon, Katja Weisel, Jeremy T Larsen, Monique C Minnema, Al-Ola A...> ;The Lancet. Haematology. 2022 Nov 1
3 citations
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the ...
Adam D Cohen, Parameswaran Hari, Myo Htut, Jesus G Berdeja, Saad Z Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D Goldberg, Jordan M Schecter, Carolyn C Jackson, Kath...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jan 1
10 citations
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Thomas Martin, Yi Lin, Mounzer Agha, Adam D Cohen, Myo Htut, A Keith Stewart, Parameswaran Hari, Jesus G Berdeja, Saad Z Usmani, Tzu-Min Yeh, Yunsi Olyslager, Jenna D ...> ;The Lancet. Haematology. 2022 Dec 1
Join now to see all

Abstracts/Posters

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Authored Content

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple MyelomaJune 2016

Press Mentions

$Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma$
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple MyelomaNovember 21st, 2022
$Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma: 2-Year Follow-up of CARTITUDE-1 Trial$
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma: 2-Year Follow-up of CARTITUDE-1 TrialJune 9th, 2022
$Carvykti Approved for Relapsed/Refractory Multiple Myeloma$
Carvykti Approved for Relapsed/Refractory Multiple MyelomaMarch 2nd, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

The Mount Sinai HospitalNew York, New York
Mount Sinai WestNew York, New York

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment